NCT01610700 - An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

July 31, 2002

Study Completion Date

July 31, 2002

Conditions

Multiple Sclerosis

Interventions

DRUG

GW-1000-02

Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.

DRUG

Placebo

Each actuation of placebo delivered the excipients only.

Trial Locations (1)

OX3 7LD

Rivermead Rehabilitation Centre, Oxford